Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Feb;82(2):160-6.
doi: 10.1016/j.radonc.2006.12.007. Epub 2007 Jan 12.

Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control

Gert O De Meerleer  1 , Valérie H Fonteyne, Luc Vakaet, Geert M Villeirs, Ludwig Denoyette, Antony Verbaeys, Nicolas Lummen, Wilfried J De Neve
Affiliations

Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control

Gert O De Meerleer et al. Radiother Oncol. 2007 Feb.

Abstract

Purpose: To report on late morbidity and biochemical relapse-free survival (bRFS) after intensity-modulated radiation therapy (IMRT) for prostate cancer.

Methods: Between 1998 and 2005 133 patients were treated with IMRT for T(1-4) N0 M0 prostate cancer. The median follow-up time was 36 months. In a first cohort, patients received a median planning target volume (PTV) dose of 74 Gy with a hard constraint on maximum rectum dose of 72 Gy (74R72, n=51). Later, median PTV and maximum rectum dose were increased to 76 and 74 Gy, respectively (76R74; n=82). We defined low-risk (n=20), intermediate-risk (n=70) and high-risk (n=43) groups. Androgen deprivation was given to patients in the intermediate- and high-risk group. Late gastro-intestinal (GI) and genito-urinary (GU) morbidity and biochemical relapse, in accordance with the ASTRO consensus, were recorded.

Results: We observed grade 2 GI (17%) and GU (19%), grade 3 GI (1%) and GU (3%) late toxicities. Except for hematuria, the median duration of side-effects was 6 months. Biochemical relapse-free survival (bRFS) at 3 and 5 years was 88% and 83%, respectively, with a significantly better 3-year bRSF for the 76R74 than for the 74R72 group (p=0.01). Five-year bRFS for patients in the low-risk, intermediate-risk and high-risk group was 100%, 94% and 74%, respectively (p<0.01).

Conclusion: IMRT for localized or locally advanced prostate cancer combines low morbidity with excellent biochemical control.

PubMed Disclaimer

Publication types

Substances